Oral palonosetron noninferior to IV formulation for CINV prevention
the ONA take:
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting (CINV), according to a study published in the October 2015 issue of the journal Supportive Care in Cancer.
For the study, a team of researchers led by Prof. Dr. med. Meinolf Karthaus of the Department of Hematology and Oncology at Klinikum Neuperlach in Munich, Germany, sought to compare the efficacy and safety of oral palonosetron with intravenous palonosetron for the prevention cisplatin-based highly emetogenic chemotherapy.
Researchers enrolled 743 chemotherapy-naive adults with malignant solid tumors initiating cisplatin-based chemotherapy. Patients were randomly assigned to receive palonosetron 0.50mg orally or 0.25mg intravenously plus oral dexamethasone.
Results showed that the complete response rate in the acute phase was higher than 86% in both treatment arms and the safety profiles were comparable.
Treatment-emergent adverse events related to palonosetron occurred in 3.2% of patients in the oral palonosetron group and 6.5% in the intravenous group.
Oral palonosetron is non-inferior to intravenous palonosetron for the prevention of cisplatin-related chemotherapy-induced nausea and vomiting.
Sign Up for Free e-newsletters
- FDA Issues Warning for Rolapitant Injectable Emulsion in the Treatment of CINV
- Risk Factors for Arterial, Venous Thrombosis Differ in Polycythemia Vera
- Resolving Vaginal Dryness in Women With a History of Breast Cancer
- BRCA Mutation Improves Prognosis for 2-year Survival in Younger-onset TNBC
- Identifying the Psychosocial Needs of Young Adults With Metastatic Cancer
- Pertuzumab Regimen Approved for Adjuvant, Neoadjuvant Therapy in Specific Breast Cancers
- Common Oncologic Emergencies That Occur With Multiple Myeloma
- Artificial Sweeteners and Cancer Risk (Fact Sheet)
- Blueberry Extract May Boost Efficacy of Radiotherapy for Cervical Cancer
- Dietary Estrogens Reduced Efficacy of Novel Breast Cancer Therapy
- Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC
- Novel Approach Can Improve Both Colorectal Cancer Screening Outcomes and Adherence
- Survival Outcomes in Relapsed Hepatocellular Carcinoma Improved With Cabozantinib
- OS Similar With Gemcitabine Plus S-1 vs Standard Therapy for Biliary Tract Cancer
- Feasibility and Outcomes of Modified Enhanced Recovery After Surgery for Nursing Management of Aged Patients Undergoing Esophagectomy
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|